|
カワムラ ヒデマサ
KAWAMURA Hidemasa
河村 英将 所属 埼玉医科大学 医学部 総合医療センター 放射線科(画像診断・核医学科、放射線腫瘍科) 職種 教授 |
|
| 論文種別 | 学術雑誌(原著) |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study |
| 掲載誌名 | 正式名：Cancers ISSNコード：2072-6694 |
| 掲載区分 | 国外 |
| 出版社 | MDPI AG |
| 巻・号・頁 | 13(15),3868-3868頁 |
| 著者・共著者 | Masahiro Onishi,Hidemasa Kawamura,Kazutoshi Murata,Tatsuro Inoue,Hiroto Murata,Yosuke Takakusagi,Noriyuki Okonogi,Yu Ohkubo,Masahiko Okamoto,Takuya Kaminuma,Tetsuo Sekihara,Takashi Nakano,Tatsuya Ohno |
| 発行年月 | 2021/07/31 |
| 概要 | This study aimed to evaluate clinical outcomes and the toxicity of intensity-modulated radiation therapy with simultaneous integrated boost (SIB-IMRT) combined with androgen-deprivation therapy for clinically node-positive (cN1) prostate cancer. We retrospectively analyzed 97 patients with cN1 prostate cancer who received SIB-IMRT between June 2008 and October 2017 at our hospital. The prescribed dosages delivered to the prostate and seminal vesicle, elective node area, and residual lymph nodes were 69, 54, and 60 Gy in 30 fractions, respectively. Kaplan–Meier analysis was used to determine 5-year biochemical relapse-free survival (bRFS), relapse-free survival (RFS), overall survival (OS), and prostate cancer-specific survival (PCSS). Toxicity was evaluated using the Common Terminology Criteria for Adverse Events ver. 4.0. Over a median follow-up duration of 60 months, the 5-year bRFS, RFS, OS, and PCSS were 85.1%, 88.1%, 92.7% and 95.0%, respectively. Acute Grade 2 genito-urinary (GU) and gastro-intestinal (GI) toxicities were observed in 10.2% and 2.1%, respectively, with no grade ≥3 toxicities being detected. The cumulative incidence rates of 5-year Grade ≥2 late GU and GI toxicities were 4.7% and 7.4%, respectively, with no Grade 4 toxicities being detected. SIB-IMRT for cN1 prostate cancer demonstrated favorable 5-year outcomes with low incidences of toxicity. |
| DOI | 10.3390/cancers13153868 |
| PMID | 34359768 |
| PermalinkURL | https://www.mdpi.com/2072-6694/13/15/3868/pdf |